← Leaderboards
James C Eisenach
Wake Forest University
$18,874,166
Attributed
$19,674,166
Total exposure
31
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,962,147 · 33
FDA$1,000,000 · 1
By mechanism
P01$27,617,443 · 8
R01$8,216,882 · 3
R37$3,745,249 · 1
U01$1,000,000 · 1
M01$382,573 · 21
Top collaborators
- Thomas J Martin4 shared
- Robert H Dworkin2 shared
- Eric C Strain2 shared
- Lena S Sun2 shared
- Dennis C. Turk2 shared
- Timothy T Houle1 shared
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainChronic PainAnalgesicsClinical ResearchOperative Surgical ProceduresAnimalsHypersensitivityResponseSpinal CordPharmaceutical PreparationsClonidineRattusSpinalInjurySiteRecoveryGrantAcuteFundingSignal TransductionAnalgesiaDisabilityFunctional DisorderPrevent
Grant awards (95)
Oxytocin: a pain disease-modifying agent in the nervous system after injury$1,804,300
P01 · FY2025 · NS
Creating PK/PD models for oxytocin action in humans and bridging to intranasal delivery$733,660
P01 · FY2025 · NS · contact PI
Oxytocin: a pain disease-modifying agent in the nervous system after injury$1,620,081
P01 · FY2024 · NS
Creating PK/PD models for oxytocin action in humans and bridging to intranasal delivery$429,435
P01 · FY2024 · NS · contact PI
Oxytocin: a pain disease-modifying agent in the nervous system after injury$1,742,343
P01 · FY2023 · NS
Creating PK/PD models for oxytocin action in humans and bridging to intranasal delivery$565,647
P01 · FY2023 · NS · contact PI
Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks and Pediatric Anesthesia Safety Initiative (ACTTION/PASI) (U01)$200,000
U01 · FY2023 · FD
Oxytocin: a pain disease-modifying agent in the nervous system after injury$1,997,998
P01 · FY2022 · NS
Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks and Pediatric Anesthesia Safety Initiative (ACTTION/PASI) (U01)$800,000
U01 · FY2022 · FD
Creating PK/PD models for oxytocin action in humans and bridging to intranasal delivery$332,998
P01 · FY2022 · NS · contact PI
Recovery from Pain and Disability after Surgery$156,451
P01 · FY2021 · GM · contact PI
Recovery from Pain and Disability after Surgery$1,411,675
P01 · FY2020 · GM · contact PI
Predicting, Understanding, and Speeding Recovery after Total Knee Arthroplasty$536,265
P01 · FY2020 · GM · contact PI
Receptor Selective Spinal Analgesia$366,910
R37 · FY2020 · GM · contact PI
Administrative Core$118,914
P01 · FY2020 · GM · contact PI
Recovery from Pain and Disability after Surgery$1,571,522
P01 · FY2019 · GM · contact PI
Predicting, Understanding, and Speeding Recovery after Total Knee Arthroplasty$677,929
P01 · FY2019 · GM · contact PI
Receptor Selective Spinal Analgesia$383,064
R37 · FY2019 · GM · contact PI
Administrative Core$118,914
P01 · FY2019 · GM · contact PI
Recovery from Pain and Disability after Surgery$1,571,522
P01 · FY2018 · GM · contact PI
Predicting, Understanding, and Speeding Recovery after Total Knee Arthroplasty$610,135
P01 · FY2018 · GM · contact PI
Receptor Selective Spinal Analgesia$383,064
R37 · FY2018 · GM · contact PI
Administrative Core$107,024
P01 · FY2018 · GM · contact PI
Recovery from Pain and Disability after Surgery$1,571,519
P01 · FY2017 · GM · contact PI
Predicting, Understanding, and Speeding Recovery after Total Knee Arthroplasty$678,629
P01 · FY2017 · GM · contact PI
Receptor Selective Spinal Analgesia$383,064
R37 · FY2017 · GM · contact PI
Administrative Core$118,913
P01 · FY2017 · GM · contact PI
Recovery from Pain and Disability after Surgery$1,739,447
P01 · FY2016 · GM · contact PI
Predicting, Understanding, and Speeding Recovery after Total Knee Arthroplasty$769,761
P01 · FY2016 · GM · contact PI
Receptor Selective Spinal Analgesia$383,290
R37 · FY2016 · GM · contact PI
Administrative Core$118,916
P01 · FY2016 · GM · contact PI
Receptor Selective Spinal Analgesia$351,907
R37 · FY2015 · GM · contact PI
Receptor Selective Spinal Analgesia$351,907
R37 · FY2014 · GM · contact PI
Receptor Selective Spinal Analgesia$339,590
R37 · FY2013 · GM · contact PI
Receptor Selective Spinal Analgesia$98,639
R37 · FY2013 · GM · contact PI
Receptor Selective Spinal Analgesia$351,907
R37 · FY2012 · GM · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$317,275
R01 · FY2012 · NS · contact PI
Receptor Selective Spinal Analgesia$351,907
R37 · FY2011 · GM · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$317,275
R01 · FY2011 · NS · contact PI
Receptor Selective Spinal Analgesia$356,447
R01 · FY2010 · GM · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$320,513
R01 · FY2010 · NS · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$66,289
R01 · FY2010 · NS · contact PI
EFFECT OF IT KETOROLAC FOLLOWING ACUTE OPIOID EXPOSURE$16,732
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: THREE WAY INTERACTION AMONG GABAPENTIN, DULOXETINE, AND DONEPEZI$6,923
M01 · FY2010 · RR · contact PI
Receptor Selective Spinal Analgesia$361,363
R01 · FY2009 · GM · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$323,750
R01 · FY2009 · NS · contact PI
Receptor Selective Spinal Analgesia$207,458
R01 · FY2009 · GM · contact PI
EFFECT OF IT KETOROLAC FOLLOWING ACUTE OPIOID EXPOSURE$12,166
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: THREE WAY INTERACTION AMONG GABAPENTIN, DULOXETINE, AND DONEPEZI$12,166
M01 · FY2009 · RR · contact PI
Receptor Selective Spinal Analgesia$396,697
R01 · FY2008 · GM · contact PI
Spinal Noradrenergic Sprouting after Nerve Injury$323,750
R01 · FY2008 · NS · contact PI
EFFECT OF IT KETOROLAC FOLLOWING ACUTE OPIOID EXPOSURE$9,806
M01 · FY2008 · RR · contact PI
Receptor Selective Spinal Analgesia$404,106
R01 · FY2007 · GM · contact PI
EFFICACY OF SPINAL KETOROLAC TO REDUCE EXPERIMENTAL PAIN$2,648
M01 · FY2007 · RR · contact PI
CLONIDINE-INDUCED SPRINAL ACETYLCHOLINE RESEARCH$1,324
M01 · FY2007 · RR · contact PI
Pharmacologic Plasticity in the Presence of Pain$1,158,290
P01 · FY2006 · NS · contact PI
Systematic Study of Selective Spinal Analgesia in Humans$382,409
R01 · FY2006 · GM · contact PI
Alpha2-Adrenergic Analgesia$353,649
R01 · FY2006 · GM · contact PI
EFFICACY OF SPINAL KETOROLAC TO REDUCE EXPERIMENTAL PAIN$22,754
M01 · FY2006 · RR · contact PI
CLONIDINE-INDUCED SPRINAL ACETYLCHOLINE RESEARCH$3,185
M01 · FY2006 · RR · contact PI
Pharmacologic Plasticity in the Presence of Pain$1,204,907
P01 · FY2005 · NS
Systematic Study of Selective Spinal Analgesia in Humans$389,772
R01 · FY2005 · GM
Alpha2-Adrenergic Analgesia$351,694
R01 · FY2005 · GM
EFFICACY OF IV KETOROLAC TO REDUCE EXPERIMENTAL PAIN$13,962
M01 · FY2005 · RR
EFFICACY OF SPINAL KETOROLAC TO REDUCE EXPERIMENTAL PAIN$10,577
M01 · FY2005 · RR
PAIN RELIEF WITH METHADONE TREATMENT: CHRONIC OPIOID USERS VS NORMAL VOLUNTEERS$9,731
M01 · FY2005 · RR
CREATING A STANDARDIZED MODEL OF MUSCLE SORENESS AND SENSITIVITY$6,346
M01 · FY2005 · RR
CLONIDINE-INDUCED SPINAL ACETYLCHOLINE RESEARCH$5,500
M01 · FY2005 · RR
MICRONEUROGRAPHIC RECORDING OF SYMPATHETIC AND AFFERENT NERVE ACTIVITY IN HUMANS$2,961
M01 · FY2005 · RR
Pharmacologic Plasticity in the Presence of Pain$1,234,922
P01 · FY2004 · NS
Alpha2-Adrenergic Analgesia$341,830
R01 · FY2004 · GM
Systematic Study of Selective Spinal Analgesia in Humans$289,604
R01 · FY2004 · GM
Efficacy of Intrathecal Ketorolac in Three Experimental Pain Conditions$21,528
M01 · FY2004 · RR
Pain Relief with Methadone Treatment: Chronic Opioid Users vs Normal Volunteers$8,392
M01 · FY2004 · RR
Pharmacologic Plasticity in the Presence of Pain$1,266,034
P01 · FY2003 · NS
Alpha2-Adrenergic Analgesia$362,824
R01 · FY2003 · GM
Systematic Study of Selective Spinal Analgesia in Humans$298,078
R01 · FY2003 · GM
Pharmacologic Plasticity in the Presence of Pain$1,236,970
P01 · FY2002 · NS
SPINAL ALPHA2 ADRENERGIC ANALGESIA$346,093
R01 · FY2002 · GM
SYSTEMATIC STUDY OF SELECTIVE SPINAL ANALGESIA IN HUMANS$278,631
R01 · FY2002 · GM
Pharmacological plasticity in humans$206,161
P01 · FY2002 · NS
Spinal alpha-2 adrenergic and opioid systems$206,161
P01 · FY2002 · NS
DIFFERENCES BETWEEN MEN &WOMEN IN ACUTE PAIN FROM INTRATHECAL NEOSTI$143,176
M01 · FY2002 · RR
PAIN RELIEF FROM ADL 10-0101 IN CHRONIC PANCREATITIS$0
M01 · FY2002 · RR
INTRATHECAL ADENOSINE AND RESPONSES TO INTRADERMAL CAPSAICIN OVER TIME$0
M01 · FY2002 · RR
SAFETY ASSESSMENT OF INTRATHECAL ADENOSINE IN HUMAN VOLUNTEERS$0
M01 · FY2002 · RR
SPINAL ALPHA2 ADRENERGIC ANALGESIA$337,916
R01 · FY2001 · GM
SYSTEMATIC STUDY OF SELECTIVE SPINAL ANALGESIA IN HUMANS$272,461
R01 · FY2001 · GM
SYSTEMATIC STUDY OF SELECTIVE SPINAL ANALGESIA IN HUMANS$487,020
R01 · FY2000 · GM
SPINAL ALPHA2 ADRENERGIC ANALGESIA$329,978
R01 · FY2000 · GM
DIFFERENCES BETWEEN MEN &WOMEN IN ACUTE PAIN FROM INTRATHECAL NEOSTI$24,232
M01 · FY2000 · RR
SAFETY ASSESSMENT OF INTRATHECAL ADENOSINE IN HUMAN VOLUNTEERS$24,232
M01 · FY2000 · RR
DOSE EQUIVALENCY OF EPIDURAL COMPARED TO INTRATHECAL CLONIDINE$24,232
M01 · FY2000 · RR
PAIN RELIEF FROM ADL 10-0101 IN CHRONIC PANCREATITIS$0
M01 · FY2000 · RR
INTRATHECAL ADENOSINE AND RESPONSES TO INTRADERMAL CAPSAICIN OVER TIME$0
M01 · FY2000 · RR